Riotsiguat - novyy preparat dlya lecheniya legochnoy gipertenzii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the new drug riociguat, which is used for the treatment of patients suffering from two forms of pulmonary hypertension - pulmonary arterial hypertension and chronic posttromboembolic pulmonary hypertension. The mechanisms of action of this drug, the results of clinical studies on the efficacy and safety, and prospects for the use of riociguat in the clinical practice are described.

Full Text

Restricted Access

About the authors

E. A Ushkalova

Email: eushk@yandex.ru

Yu. Sh Gushchina

References

  1. FDA Panel Recommends Riociguat (Adempas) for 2 Pulmonary Hypertension Indications http:// www.medscape.com/viewarticle/809083
  2. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. August 2013. http:// www.ema.europa.eu/docs/en_GB/document_ library/Report/2013/08/WC500147012.pdf
  3. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. EurRespir Rev 2009;18:35-41
  4. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007;49:1128-33.
  5. Archer S. Riociguat for Pulmonary Hypertension -A Glass Half Full. N Engl J Med 2013; 369:386-88.
  6. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009;191:277-308.
  7. Schermuly R, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881-91.
  8. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33(4):785-92.
  9. Frey R, M ck W, Unger S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008;48(8):926-34.
  10. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006;129:417-25.
  11. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat Treatment in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or Pulmonary Arterial Hypertension (PAH). American Thoracic Society (ATS) conference, San Diego, May 2009. Poster Presentation.
  12. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29.
  13. Ghofrani HA, Gali N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369(4):330-40.
  14. Ghofrani, HA, et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double- blind, placebo-controlled study (PATENT-1). CHEST 2012, Atlanta, USA. Oral presentation. Abstract 1462799.
  15. Simonneau G, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): A Phase III long-term extension study (CHEST-2). 5th World Symposium of Pulmonary Hypertension (WSPH) 2013, Nice, France. Poster Presentation.
  16. Rubin, LJ, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): A Phase III Long-term Extension Study (PATENT-2). ATS 2013, Philadelphia, USA. Oral Presentation.
  17. Jais X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-34.
  18. Ryan JJ, Rich S, Archer SL. Pulmonary endarterectomy surgery -- a technically demanding cure for WHO Group IV Pulmonary Hypertension: requirements for centres of excellence and availability in Canada. Can J Cardiol 2011; 27:671-74.
  19. Freed DH, Thomson BM, Berman M, et al. Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension. J Thorac Cardiovasc Surg 2011;141:383-87.
  20. Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007;115:2153-58.
  21. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1 122-27.
  22. Thistlethwaite PA, Kemp A, Du L, Madani MM, Jamieson SW. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2006;131:307-13.
  23. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003;76:1457-62.
  24. Ghofrani H-A, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-99.
  25. Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev 2013;22(129):217-26.
  26. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079-87.
  27. Archer SL, Djaballah K, Humbert M, et al. Nitric oxide deficiency in fenfluramine and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1061-67.
  28. Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;188(6):639-46.
  29. Evgenov O, Pacher P, Schmidt PM, et al. NO-independent Stimulators and Activators of Soluble Guanylate Cyclase: Discovery and Therapeutic Potential. Nature Reviews Drug Discovery 2006;5:755-69.
  30. Nossaman B, Pankey E, Kadowitz P. Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. Crit Care Res Pract 2012;2012:290805.
  31. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44.
  32. Steiner MK, Preston IR. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension Vasc Health Risk Manag. 2008;4(5):943-52.
  33. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502-11.
  34. Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013;41(4):853-60.
  35. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121:2045-66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies